

## Freedom of Information request 211-21

---

### Request

I am analysing the treatment of lung cancer and would greatly appreciate if you could answer the following questions:

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib
- Alectinib
- Atezolizumab monotherapy
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
- Bevacizumab
- Brigatinib
- Ceritinib
- Crizotinib
- Dacomitinib
- Dabrafenib with Trametinib
- Docetaxel monotherapy
- Durvalumab
- Erlotinib
- Gefitinib
- Gemcitabine
- Nintedanib with Docetaxel
- Nivolumab
- Osimertinib
- Paclitaxel
- Pembrolizumab monotherapy
- Pembrolizumab chemo in combination
- Pemetrexed with Carboplatin
- Pemetrexed with Cisplatin
- Vinorelbine and cisplatin/carboplatin
- Any other active systemic anti-cancer therapy (SACT)
- Palliative care only

Q2. Could you please provide the total number of patients treated with any systemic anti-cancer therapy (SACT) in the last three months for:

- Total non-small cell lung cancer (NSCLC)
- Squamous non-small cell lung cancer (Sq NSCLC)
- Non-squamous non-small cell lung cancer (Non-Sq NSCLC)

Q3. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

## Response

1. Please see table below:

Afatinib	<5
Alectinib	<5
Atezolizumabmonotherapy	0
Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	0
Bevacizumab	0
Brigatinib	0
Ceritinib	0
Crizotinib	0
Dacomitinib	0
Dabrafenib with Trametinib	0
Docetaxelmonotherapy	0
Durvalumab	0
Erlotinib	0
Gefitinib	0
Gemcitabine	0
Nintedanib with Docetaxel	0
Nivolumab	0
Osimertinib	0
Paclitaxel	0
Pembrolizumabmonotherapy	6
Pembrolizumab chemo in combination	5
Pemetrexed with Carboplatin	<5
Pemetrexed with Cisplatin	0
Vinorelbine and cisplatin/carboplatin	0
Any other active systemic anti-cancer therapy (SACT)	0
Palliative care only	<5

2. Please see table below:

Total non-small cell lung cancer (NSCLC)	16
Squamous non-small cell lung cancer (Sq NSCLC)	<5
Non-squamous non-small cell lung cancer (Non-Sq NSCLC)	13

3. No NHS Borders does not, but we do have access to trials within NHS Lothian and currently there are <5 patients receiving treatment for NSCLC within a clinical trial.

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or [foi.enquiries@borders.scot.nhs.uk](mailto:foi.enquiries@borders.scot.nhs.uk).

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **211-21** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.